IRONWOOD PHARMACEUTICALS, INC. Repayments of Long-Term Debt
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Repayments of Long-Term Debt of $134.26 million for the 12-month period ending 2017-12-31, per its 10-K filed 2020-02-13.
Discontinued › Cash Flow › Financing Activities
us-gaap:RepaymentsOfLongTermDebt · last filed 2020-02-13
- IRONWOOD PHARMACEUTICALS, INC. repayments of long-term debt for the quarter ending 2017-12-31 was $0.00, a 100.00% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. repayments of long-term debt for the quarter ending 2017-09-30 was $0.00, a 100.00% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. repayments of long-term debt for the quarter ending 2017-06-30 was $0.00, a 100.00% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. repayments of long-term debt for the quarter ending 2017-03-31 was $134.26M, a 2434.13% increase year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. repayments of long-term debt for fiscal 2017 was $134.26M, a 399.69% increase from fiscal 2016.
- IRONWOOD PHARMACEUTICALS, INC. repayments of long-term debt for fiscal 2016 was $26.87M, a 111.36% increase from fiscal 2015.
- IRONWOOD PHARMACEUTICALS, INC. repayments of long-term debt for fiscal 2015 was $12.71M.
| Period end | Repayments of Long-term Debt 3 month | Repayments of Long-term Debt 6 month | Repayments of Long-term Debt 9 month | Repayments of Long-term Debt 12 month |
|---|---|---|---|---|
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | $0.00 derived: sum of 2 quarters · filed 2020-02-13 | $0.00 derived: sum of 3 quarters · filed 2020-02-13 | $134.26M 10-K · filed 2020-02-13 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $0.00 derived: sum of 2 quarters · filed 2018-11-06 | $134.26M 10-Q · filed 2018-11-06 | $142.66M derived: sum of 4 quarters · filed 2019-02-25 |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06 | $134.26M 10-Q · filed 2018-08-06 | $142.66M derived: sum of 3 quarters · filed 2019-02-25 | $149.83M derived: sum of 4 quarters · filed 2019-02-25 |
| 2017-03-31 | $134.26M 10-Q · filed 2018-05-04 | $142.66M derived: sum of 2 quarters · filed 2019-02-25 | $149.83M derived: sum of 3 quarters · filed 2019-02-25 | $155.83M derived: sum of 4 quarters · filed 2019-02-25 |
| 2016-12-31 | $8.40M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-25 | $15.57M derived: sum of 2 quarters · filed 2019-02-25 | $21.57M derived: sum of 3 quarters · filed 2019-02-25 | $26.87M 10-K · filed 2019-02-25 |
| 2016-09-30 | $7.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $13.16M derived: sum of 2 quarters · filed 2017-11-02 | $18.46M 10-Q · filed 2017-11-02 | |
| 2016-06-30 | $6.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $11.30M 10-Q · filed 2017-08-03 | ||
| 2016-03-31 | $5.30M 10-Q · filed 2017-05-08 | |||
| 2015-12-31 | $12.71M 10-K · filed 2018-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |